Algorithm designed to guide treat-and-extend anti-VEGF dosing

A new algorithm may be used to tailor treat-and-extend regimens with intravitreal anti-VEGF agents to individual patients with retinal disease, according to a study.The algorithm was developed using data from 11 published studies on treat-and-extend regimens with intravitreal Avastin (bevacizumab, Genentech) Lucentis (ranibizumab, Genentech) and Eylea (aflibercept, Regeneron).